Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Howmet Aerospace Inc (HWM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Howmet Aerospace Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Howmet Aerospace Inc trades at $270.5 (market cap $110.20B). The key difference: Howmet Aerospace Inc is far larger — about 24.5× ACADIA Pharmaceuticals Inc.'s market cap, and Howmet Aerospace Inc pays a 0.17% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | HWM | |
|---|---|---|
Market Cap | $4.49B | $110.20B |
Sector | Health | Industrials |
52-Week High | $28.06 | $283.23 |
52-Week Low | $20.06 | $171.00 |
Enterprise Value | $3.69B | $112.45B |
Dividend Yield | — | 0.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Howmet Aerospace (HWM) trades at $277.91, up 2.77% today, reflecting strong momentum in the aerospace and defense sectors. The stock exhibits bullish technical signals with support at $273 and resistance at $282. Recent earnings show mixed results, with Q1 2026 missing estimates, but robust profitability metrics like a 20.22% net margin and 33.98% ROE highlight operational strength. Positive sentiment is driven by defense demand and commercial aerospace growth, as noted in Zacks Investment Research articles from July 2026.
Outlook remains positive with an 83% analyst buy rating and a $313.50 consensus price target, suggesting 13% upside. Risks include premium valuations (P/E of 62.74) and execution challenges amid economic uncertainty. The company's cash flow growth and dividend payments support investor confidence, but high multiples warrant caution for new entries.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Howmet Aerospace Inc
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →
